CO2017009130A2 - Métodos para preparar buprenorfina - Google Patents
Métodos para preparar buprenorfinaInfo
- Publication number
- CO2017009130A2 CO2017009130A2 CONC2017/0009130A CO2017009130A CO2017009130A2 CO 2017009130 A2 CO2017009130 A2 CO 2017009130A2 CO 2017009130 A CO2017009130 A CO 2017009130A CO 2017009130 A2 CO2017009130 A2 CO 2017009130A2
- Authority
- CO
- Colombia
- Prior art keywords
- buprenorphine
- acetate salts
- methods
- salts
- impurities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
RESUMEN La presente descripción hace referencia a sales de acetato de buprenorfina y sus anhidros, solvatos, hidratos y formas cristalinas y en la que las sales de acetato de buprenorfina se encuentran esencialmente libres de impurezas. De manera adicional, la descripción provee un método para preparar las sales de acetato, la base libre de buprenorfina preparada a partir de las sales de acetato, otras sales preparadas a partir de la base libre y las composiciones farmacéuticas de estas esencialmente libre de impurezas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562131114P | 2015-03-10 | 2015-03-10 | |
PCT/IB2016/051332 WO2016142877A1 (en) | 2015-03-10 | 2016-03-09 | Acetate salt of buprenorphine and methods for preparing buprenorphine |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017009130A2 true CO2017009130A2 (es) | 2017-11-21 |
Family
ID=55524412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0009130A CO2017009130A2 (es) | 2015-03-10 | 2017-09-07 | Métodos para preparar buprenorfina |
Country Status (19)
Country | Link |
---|---|
US (6) | US10406152B2 (es) |
EP (1) | EP3283490A1 (es) |
JP (2) | JP6660399B2 (es) |
KR (2) | KR20170137738A (es) |
CN (1) | CN107660207B (es) |
AR (1) | AR103902A1 (es) |
AU (2) | AU2016230750B2 (es) |
BR (1) | BR112017019357A2 (es) |
CA (2) | CA3104099A1 (es) |
CO (1) | CO2017009130A2 (es) |
EA (1) | EA201792014A1 (es) |
IL (1) | IL254384A0 (es) |
MA (1) | MA45902A (es) |
MX (1) | MX2017011606A (es) |
NZ (1) | NZ735736A (es) |
PH (1) | PH12017501641A1 (es) |
SG (1) | SG11201707350TA (es) |
TW (2) | TW202037597A (es) |
WO (1) | WO2016142877A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015023036A2 (pt) | 2013-03-15 | 2017-11-14 | Univ Leland Stanford Junior | método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina |
US11124814B2 (en) | 2013-11-04 | 2021-09-21 | The Board Of Trustees Of The Leland Stanford Junior University | Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same |
AU2016230750B2 (en) * | 2015-03-10 | 2019-05-30 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
CA2983419A1 (en) | 2015-05-04 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same |
IL255136B2 (en) | 2015-05-08 | 2023-09-01 | Univ Leland Stanford Junior | Methods for generating epimerases and benzylisoquinoline alkaloids |
AU2017345328C1 (en) | 2016-10-18 | 2023-03-02 | Antheia, Inc. | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids |
BR112020002050A2 (pt) | 2017-08-03 | 2020-09-08 | Antheia, Inc. | epimerases engenheiradas alcaloides benzilisoquinolina e métodos de produção de alcaloides benzilisoquinolina |
KR20210021459A (ko) * | 2018-05-11 | 2021-02-26 | 에일러 파마슈티컬스 아이엔씨. | 오래 지속되는 주사용 제제와 부프레노핀 유도체 |
WO2023246865A1 (en) * | 2022-06-24 | 2023-12-28 | Alar Pharmaceuticals Inc. | Stable pharmaceutical composition of buprenorphine and preparation method and use thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3275638A (en) * | 1966-09-27 | Chjcoo- | ||
US2191786A (en) | 1938-03-18 | 1940-02-27 | C A Miketta | Continuous process for making adipic acid |
BE466549A (es) | 1945-07-17 | |||
US3355486A (en) | 1965-01-08 | 1967-11-28 | Fmc Corp | Continuous process of synthesizing amino-iminomethane-sulfinic acid |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
GB1312447A (en) | 1969-05-14 | 1973-04-04 | Nat Res Dev | Method of continuous addition of a component to a chemical or biological system and apparatus therefor |
US4217287A (en) | 1971-10-06 | 1980-08-12 | Gulf Research & Development Company | Epoxidation of alpha-olefins |
US3936462A (en) * | 1972-05-26 | 1976-02-03 | Sterling Drug Inc. | 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
GB1520139A (en) | 1976-06-08 | 1978-08-02 | Ferranti Ltd | Gyroscopic apparatus |
US4362870A (en) * | 1980-01-16 | 1982-12-07 | Regents Of The University Of Minnesota | Selective opioid receptor alkylating agents |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4830028A (en) | 1987-02-10 | 1989-05-16 | R. J. Reynolds Tobacco Company | Salts provided from nicotine and organic acid as cigarette additives |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6344211B1 (en) | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
TW452907B (en) | 1999-11-22 | 2001-09-01 | Winbond Electronics Corp | Testing device and method of positive mobile ion contamination |
US6994827B2 (en) | 2000-06-03 | 2006-02-07 | Symyx Technologies, Inc. | Parallel semicontinuous or continuous reactors |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US7560445B2 (en) | 2005-07-06 | 2009-07-14 | Taro Pharmaceuticals North America, Inc. | Process for preparing malathion for pharmaceutical use |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
JP2010511726A (ja) | 2006-12-04 | 2010-04-15 | ノランコ・インコーポレーテツド | 14−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法 |
CA2671860C (en) | 2006-12-11 | 2016-07-12 | Alcon Research Ltd. | Process for preparing substantially pure fluorescein |
EP2311498A4 (en) * | 2008-08-05 | 2013-07-24 | Medrx Co Ltd | EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF |
US8492547B2 (en) * | 2009-07-09 | 2013-07-23 | Mallinckrodt Llc | Method for the enrichment of buprenorphine using chromatographic techniques |
NZ609874A (en) * | 2010-09-30 | 2014-10-31 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
SG11201403162XA (en) | 2011-12-12 | 2014-10-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
WO2013156850A1 (en) | 2012-04-17 | 2013-10-24 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
ES2748803T3 (es) * | 2012-12-31 | 2020-03-18 | Rhodes Tech | Procedimiento para preparar 6,14-etenomorfinanos sustituidos en 7, 6,14-etanomorfinanos sustituidos en 7 |
DK2810646T3 (en) | 2013-06-04 | 2016-10-31 | Lts Lohmann Therapie Systeme Ag | A transdermal |
CN103408553B (zh) * | 2013-08-20 | 2016-02-03 | 宜昌人福药业有限责任公司 | 一种氢吗啡酮酸式盐的精制工艺 |
US8846923B1 (en) * | 2013-12-18 | 2014-09-30 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
AU2016230750B2 (en) * | 2015-03-10 | 2019-05-30 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
-
2016
- 2016-03-09 AU AU2016230750A patent/AU2016230750B2/en not_active Ceased
- 2016-03-09 KR KR1020177028535A patent/KR20170137738A/ko active Application Filing
- 2016-03-09 CA CA3104099A patent/CA3104099A1/en not_active Abandoned
- 2016-03-09 KR KR1020207011729A patent/KR20200045010A/ko not_active Application Discontinuation
- 2016-03-09 CA CA2977732A patent/CA2977732C/en not_active Expired - Fee Related
- 2016-03-09 BR BR112017019357A patent/BR112017019357A2/pt not_active IP Right Cessation
- 2016-03-09 US US15/507,453 patent/US10406152B2/en active Active
- 2016-03-09 MA MA045902A patent/MA45902A/fr unknown
- 2016-03-09 NZ NZ735736A patent/NZ735736A/en not_active IP Right Cessation
- 2016-03-09 CN CN201680027202.2A patent/CN107660207B/zh not_active Expired - Fee Related
- 2016-03-09 SG SG11201707350TA patent/SG11201707350TA/en unknown
- 2016-03-09 EP EP16709607.2A patent/EP3283490A1/en not_active Withdrawn
- 2016-03-09 WO PCT/IB2016/051332 patent/WO2016142877A1/en active Application Filing
- 2016-03-09 EA EA201792014A patent/EA201792014A1/ru unknown
- 2016-03-09 MX MX2017011606A patent/MX2017011606A/es unknown
- 2016-03-09 JP JP2017547399A patent/JP6660399B2/ja not_active Expired - Fee Related
- 2016-03-10 AR ARP160100641A patent/AR103902A1/es unknown
- 2016-03-10 TW TW109106564A patent/TW202037597A/zh unknown
- 2016-03-10 TW TW105107434A patent/TWI699367B/zh not_active IP Right Cessation
-
2017
- 2017-03-01 US US15/446,197 patent/US9926329B2/en active Active
- 2017-09-07 CO CONC2017/0009130A patent/CO2017009130A2/es unknown
- 2017-09-07 IL IL254384A patent/IL254384A0/en unknown
- 2017-09-08 PH PH12017501641A patent/PH12017501641A1/en unknown
-
2018
- 2018-02-12 US US15/894,520 patent/US10278967B2/en active Active
-
2019
- 2019-05-10 AU AU2019203308A patent/AU2019203308A1/en not_active Abandoned
- 2019-06-19 US US16/446,397 patent/US10874662B2/en active Active
- 2019-06-19 US US16/446,373 patent/US10835528B2/en active Active
- 2019-10-10 JP JP2019186901A patent/JP2020033359A/ja active Pending
-
2020
- 2020-10-29 US US17/084,588 patent/US20210046066A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017009130A2 (es) | Métodos para preparar buprenorfina | |
CO2017012786A2 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
ECSP21072161A (es) | Composiciones de liberación retardada de linaclotida | |
CO2017012893A2 (es) | Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas | |
CU24466B1 (es) | Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen | |
GT201400297A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
BR112017019409A2 (pt) | forma cristalina de ribosídeo de nicotinamida | |
CR20160033A (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida | |
UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
AR105434A1 (es) | Proceso para preparar pridopidina | |
DOP2017000064A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
ECSP16074478A (es) | Compuestos novedosos | |
BR112017000135B8 (pt) | Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico | |
CR20160224A (es) | Composición herbicida que comprende inhibidores ACC | |
CU20160168A7 (es) | Proceso para preparar cianhidrinas que contienen fósforo | |
MX2018002731A (es) | Proceso para la elaboracion de esteres de cianohidrina que contienen fosforo. | |
CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
MX2018002730A (es) | Proceso para producir esteres de cianhidrina que contienen fosforo. | |
MX2018002729A (es) | Proceso para la elaboracion de esteres de cianohidrina que contienen fosforo. | |
MX2018002726A (es) | Proceso para producir esteres de cianhidrina que contienen fosforo. | |
AR101951A1 (es) | Síntesis de ent-progesterona e intermediarios de la misma | |
BR112018015037A2 (pt) | método de produção de composição |